Biswajit Dubashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Biswajit Dubashi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
A. Jain
Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Dhanvantari Nagar, Puducherry, India
2 shared publications- Bheemanathi Hanuman Srinivas
Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
2 shared publications - Debdatta Basu
Department of Pathology, JIPMER, Pondicherry, India
2 shared publications - Ankit Jain
Mid-North Coast Cancer Institute, Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia
1 shared publication B. Karthikeyan
Department of Medical Oncology, Regional Cancer Centre, The Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India
1 shared publication- ChandraMohan Ramasamy
Department of Medicine, JIPMER, Puducherry, 605006 India
1 shared publication
Latest Publications
- Open Access
- 24 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32929
Clinicopathological Profile of Paraprotein-Associated Kidney Disease in Monoclonal Gammopathies: An Observational Study
Renal involvement in monoclonal gammopathies presents with different clinico-morphological patterns and can manifest at the onset or the late phase of hematological disease, or after chemotherapy. The spectrum is ever-expanding with advancements in diagnostic methods. Renal biopsy is needed for accurate diagnosis, as each of these patterns carries therapeutic and prognostic implications. A total of 41 cases of monoclonal gammopathies were included in the study. Clinical, biochemical, and hematological details were obtained, and pathological variables were observed. Patients were followed till the maximum possible period, and treatment history and follow-up creatinine details were collected. The spectrum of renal biopsy lesions observed included light chain cast nephropathy (LCCN) n=19, amyloidosis n=11, monoclonal immunoglobulin deposition disease (MIDD) n=6, and proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID) n=5; 10 of these cases can be categorized as monoclonal gammopathy of renal significance (MGRS). Acute kidney injury (AKI) (41%) is the predominant clinical presentation in general whereas the majority of amyloidosis cases presented with nephrotic and sub-nephrotic proteinuria. LCCN cases had high serum creatinine and calcium, positivity for M-spike, as well as a high FLC ratio, compared to the other types. Around 100% of LCCN and MIDD patients had myeloma and 100% of PGNMID cases had normal marrow. More than three-fourths of patients were diagnosed with monoclonal gammopathies with biochemical and hematological workups after an initial kidney biopsy. The clinicopathological profile of these patients had a broad spectrum but there were still some consistent findings within the different types. A subgroup of patients (MGRS) had undetectable serum paraproteins but had monoclonal immunoglobulin deposition in the kidney.
- 24 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32929
Open AccessClinicopathological Profile of Paraprotein-Associated Kidney Disease in Monoclonal Gammopathies: An Observational Study
Renal involvement in monoclonal gammopathies presents with different clinico-morphological patterns and can manifest at the onset or the late phase of hematological disease, or after chemotherapy. The spectrum is ever-expanding with advancements in diagnostic methods. Renal biopsy is needed for accurate diagnosis, as each of these patterns carries therapeutic and prognostic implications. A total of 41 cases of monoclonal gammopathies were included in the study. Clinical, biochemical, and hematological details were obtained, and pathological variables were observed. Patients were followed till the maximum possible period, and treatment history and follow-up creatinine details were collected. The spectrum of renal biopsy lesions observed included light chain cast nephropathy (LCCN) n=19, amyloidosis n=11, monoclonal immunoglobulin deposition disease (MIDD) n=6, and proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID) n=5; 10 of these cases can be categorized as monoclonal gammopathy of renal significance (MGRS). Acute kidney injury (AKI) (41%) is the predominant clinical presentation in general whereas the majority of amyloidosis cases presented with nephrotic and sub-nephrotic proteinuria. LCCN cases had high serum creatinine and calcium, positivity for M-spike, as well as a high FLC ratio, compared to the other types. Around 100% of LCCN and MIDD patients had myeloma and 100% of PGNMID cases had normal marrow. More than three-fourths of patients were diagnosed with monoclonal gammopathies with biochemical and hematological workups after an initial kidney biopsy. The clinicopathological profile of these patients had a broad spectrum but there were still some consistent findings within the different types. A subgroup of patients (MGRS) had undetectable serum paraproteins but had monoclonal immunoglobulin deposition in the kidney.
- 1 January 2022
- Published by Wolters Kluwer Health in AJSP: Reviews and Reports
- Vol. 27 (1) , 25-28
Anaplastic Large Cell Lymphoma of the Breast With Simultaneous Peripheral Blood and Marrow Involvement
Anaplastic large cell lymphoma (ALCL) of the breast is an extremely rare hematolymphoid malignancy and is characteristically associated with breast implants. Among the primary hematolymphoid malignancies arising from the breast, T-cell lymphomas are extremely rare, and among T-cell lymphomas, ALCL has a better prognosis. We present the case of a 30-year-old woman with a diagnosis of ALCL without any breast implants and with simultaneous involvement of bone marrow and peripheral blood. Pathologists should be aware of this entity and should include it in the differential diagnoses when evaluating a breast biopsy that shows a high-grade anaplastic morphology.
- 1 January 2022
- Published by Wolters Kluwer Health in AJSP: Reviews and Reports
- Vol. 27 (1) , 25-28
Anaplastic Large Cell Lymphoma of the Breast With Simultaneous Peripheral Blood and Marrow Involvement
Anaplastic large cell lymphoma (ALCL) of the breast is an extremely rare hematolymphoid malignancy and is characteristically associated with breast implants. Among the primary hematolymphoid malignancies arising from the breast, T-cell lymphomas are extremely rare, and among T-cell lymphomas, ALCL has a better prognosis. We present the case of a 30-year-old woman with a diagnosis of ALCL without any breast implants and with simultaneous involvement of bone marrow and peripheral blood. Pathologists should be aware of this entity and should include it in the differential diagnoses when evaluating a breast biopsy that shows a high-grade anaplastic morphology.
- Open Access
- 1 December 2013
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 5 (4) , 111
Late effect clinic – An integral part of childhood cancer treatment
- 1 December 2013
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 5 (4) , 111
Open AccessLate effect clinic – An integral part of childhood cancer treatment
- Open Access
- 9 October 2012
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 30 (1) , 59-61
Atypical Mycobacterial Infection in Hairy Cell Leukemia Treated with Cladribine
We report a case of hairy cell leukemia who improved after cladribine but succumbed to disseminated atypical mycobacterial infection 2 months after completing cladribine.
- 9 October 2012
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 30 (1) , 59-61
Open AccessAtypical Mycobacterial Infection in Hairy Cell Leukemia Treated with Cladribine
We report a case of hairy cell leukemia who improved after cladribine but succumbed to disseminated atypical mycobacterial infection 2 months after completing cladribine.
- Open Access
- 1 April 2011
- Published by MDPI AG in Current Oncology
- Vol. 18 (2) , 101-102
Chronic Lymphocytic Leukemia and Breast Cancer as Synchronous Primary in a Male—A Rare Combination
Second malignancies are known to be associated with chronic lymphocytic leukemia (CLL).
- 1 April 2011
- Published by MDPI AG in Current Oncology
- Vol. 18 (2) , 101-102
Open AccessChronic Lymphocytic Leukemia and Breast Cancer as Synchronous Primary in a Male—A Rare Combination
Second malignancies are known to be associated with chronic lymphocytic leukemia (CLL).
- Open Access
- 1 November 2010
- Published by MDPI AG in Current Oncology
- Vol. 17 (6) , 71-72
Arterial Occlusion Precipitated by Cisplatinbased Chemotherapy
Cisplatin-based therapy is curative in testicular cancer. Adverse effects of cisplatin-based chemotherapy include dose-dependent myelosuppression, nephrotoxicity, neurotoxicity, and ototoxicity. By contrast, chemotherapy-associated vascular complications are unpredictable. Few incidents of digital gangrene with cisplatin have been reported. Here, we present a patient who developed arterial occlusion leading to gangrene of the toe after cisplatinbased chemotherapy.
- 1 November 2010
- Published by MDPI AG in Current Oncology
- Vol. 17 (6) , 71-72
Open AccessArterial Occlusion Precipitated by Cisplatinbased Chemotherapy
Cisplatin-based therapy is curative in testicular cancer. Adverse effects of cisplatin-based chemotherapy include dose-dependent myelosuppression, nephrotoxicity, neurotoxicity, and ototoxicity. By contrast, chemotherapy-associated vascular complications are unpredictable. Few incidents of digital gangrene with cisplatin have been reported. Here, we present a patient who developed arterial occlusion leading to gangrene of the toe after cisplatinbased chemotherapy.
- 1 March 2010
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 32 (2) , e54-e56
Clinical Presentation and Outcome of Pediatric Ovarian Germ Cell Tumor: A Study of 40 Patients
Germ cell tumor is a rare malignancy accounting for 3% of all pediatric tumors. They are highly curable malignancies. The aim of this study was to evaluate the clinical presentation, management, and outcome in this subset. The study population included 40 patients with age less than 18 years at diagnosis. They were treated in Cancer Institute Chennai, India from 1990 to 2002. They were analyzed for the various clinical, pathologic presentations, and survival outcomes. Actuarial method was used to estimate the overall survival and relapse-free survival. The mean age of the study group was 14+2.7 years with most of the patients being postpubertal. The common histologies being mixed germ cell tumor (32%) and dysgerminoma (27%). Ten percent of patients presented with ovarian torsion. Sixty-two percent of patients presented in advanced stage. Fertility preservation surgery was possible in 70% of the patients. Relapses were seen in 25% of the patients. The median duration of follow-up was 7.5 years with a 5 years disease-free survival of 72.8% and overall survival of 94.9%. Most of the patients achieved a good quality of life with normal menstrual cycles. This study confirms an excellent outcome for girls with ovarian germ cell tumor, although majority of the patients presented in advanced stage. Patients with initial histology of Teratoma and Mixed germ cell tumor relapsed frequently. The mainstay of treatment being fertility preservation and cisplatin-based chemotherapy.
- 1 March 2010
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 32 (2) , e54-e56
Clinical Presentation and Outcome of Pediatric Ovarian Germ Cell Tumor: A Study of 40 Patients
Germ cell tumor is a rare malignancy accounting for 3% of all pediatric tumors. They are highly curable malignancies. The aim of this study was to evaluate the clinical presentation, management, and outcome in this subset. The study population included 40 patients with age less than 18 years at diagnosis. They were treated in Cancer Institute Chennai, India from 1990 to 2002. They were analyzed for the various clinical, pathologic presentations, and survival outcomes. Actuarial method was used to estimate the overall survival and relapse-free survival. The mean age of the study group was 14+2.7 years with most of the patients being postpubertal. The common histologies being mixed germ cell tumor (32%) and dysgerminoma (27%). Ten percent of patients presented with ovarian torsion. Sixty-two percent of patients presented in advanced stage. Fertility preservation surgery was possible in 70% of the patients. Relapses were seen in 25% of the patients. The median duration of follow-up was 7.5 years with a 5 years disease-free survival of 72.8% and overall survival of 94.9%. Most of the patients achieved a good quality of life with normal menstrual cycles. This study confirms an excellent outcome for girls with ovarian germ cell tumor, although majority of the patients presented in advanced stage. Patients with initial histology of Teratoma and Mixed germ cell tumor relapsed frequently. The mainstay of treatment being fertility preservation and cisplatin-based chemotherapy.